Abstract
Objective: To investigate the efficacy of neoadjuvant chemotherapy with modified FOLFOX regimen for patients with advanced gastric cancer. Methods: Between September 2006 and September 2008, a total of 80 patients with advanced gastric cancer were divided into neoadjuvant chemotherapy+surgery group (Group A) and surgery alone group (Group B), with 40 patients in each group. In Group A, we administered neoadjuvant chemotherapy with OXA 100mg/m~2 iv d1(2hr), CF 400mg/m~2 iv d1 (2hr), and 5-FU 2 400mg/m~3 civ d1(46hr). After 2 treatment cycles, CT was performed in all patients. Results: In Group A, the clinical efficacy (CR+PR) was 52.5% (21/40); the SD was 37.5% (15/40), and PD was 10.0% (4/40). The overall resectability rate was 92.5% (37/40); and the curative resection rate was 77.5% (31/40); only 7.5% (3/40) had exp.lap. In Group B, the overall resectability rate was 75.0% (30/40); the curative resection rate was 52.5% (21/40); and 22.5% (9/40) had exp.lap. No mortality was observed. No significant differences were found in toxicities between the two groups. Conclusion: Neoadjuvant chemotherapy with modified FOLFOX regimen is safe and effective for patients with advanced gastric cancer and can increase the overall resectability rate and the curative resection rate.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.